Home > Publications database > Impact of transurethral resection of bladder tumors on sexual function and quality of life using ePROMs in patients with bladder cancer- a prospective cohort study. > print

001     301920
005     20250615021102.0
024 7 _ |a 10.1007/s00345-025-05726-x
|2 doi
024 7 _ |a pmid:40495081
|2 pmid
024 7 _ |a 0724-4983
|2 ISSN
024 7 _ |a 1433-8726
|2 ISSN
024 7 _ |a altmetric:178045238
|2 altmetric
037 _ _ |a DKFZ-2025-01190
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Menold, H. S.
|0 0009-0006-7815-0676
|b 0
245 _ _ |a Impact of transurethral resection of bladder tumors on sexual function and quality of life using ePROMs in patients with bladder cancer- a prospective cohort study.
260 _ _ |a Heidelberg
|c 2025
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1749647454_17637
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The impact of transurethral resection of bladder tumors (TURBT) on patients' quality of life (QoL) and sexual function is underrepresented in the literature. Therefore, this study aimed to evaluate sexual function and QoL following TURBT, using electronic patient reported outcome questionnaires (ePROMs).Patients undergoing TURBT were surveyed using a digital ePROM system (Heartbeat Medical). Sexual function and QoL were assessed using the Male/Female LUTS Sexual Function module (ICIQ-MLUTSsex/FLUTSsex) at 3, 6 and 12 months postoperatively and the EORTC QLQ-NMIBC 24. Linear mixed-effects models were used to identify influencing factors, adjusting for baseline. Repeated measures ANOVA tested differences in domain scores over time.197 patients completed the survey, of whom 77% (n = 151) were men. Based on the ICIQ-MLUTSsex sexual function was significantly impaired at 3, 6 and 12-months postoperatively compared to baseline (p = 0.005; p = 0.004; p = 0.017). Age was the strongest factor for reduced male sexual function (ICIQ-MLUTSsex and QLQ-NMIBC24: p < 0.001). Subdomain analysis revealed negative effects on ejaculation (p = 0.044) and urinary symptoms (p = 0.031) up to 6 months. No differences were observed for the female population.TURBT may result in long-term impairment of sexual function in male patients, whereas no such effect was observed in female patients within this cohort.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Bladder cancer; urinary bladder neoplasms
|2 Other
650 _ 7 |a Patient-reported outcome measurements
|2 Other
650 _ 7 |a Quality of life
|2 Other
650 _ 7 |a Sexual function
|2 Other
650 _ 7 |a TURB
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Quality of Life
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Urinary Bladder Neoplasms: surgery
|2 MeSH
650 _ 2 |a Patient Reported Outcome Measures
|2 MeSH
650 _ 2 |a Sexual Dysfunction, Physiological: etiology
|2 MeSH
650 _ 2 |a Cystectomy: methods
|2 MeSH
650 _ 2 |a Cystectomy: adverse effects
|2 MeSH
650 _ 2 |a Cohort Studies
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Postoperative Complications
|2 MeSH
700 1 _ |a Gruene, B.
|b 1
700 1 _ |a Koenig, J.
|b 2
700 1 _ |a Lenhart, M.
|b 3
700 1 _ |a Waldbillig, F.
|b 4
700 1 _ |a Kowalewski, K. F.
|0 P:(DE-He78)4bf55e48eb0a1cae557e0b392d01bddf
|b 5
|u dkfz
700 1 _ |a Michel, M. S.
|b 6
700 1 _ |a Kriegmair, M. C.
|b 7
700 1 _ |a Neuberger, M.
|b 8
700 1 _ |a Wessels, F.
|b 9
773 _ _ |a 10.1007/s00345-025-05726-x
|g Vol. 43, no. 1, p. 370
|0 PERI:(DE-600)1463303-6
|n 1
|p 370
|t World journal of urology
|v 43
|y 2025
|x 0724-4983
909 C O |o oai:inrepo02.dkfz.de:301920
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)4bf55e48eb0a1cae557e0b392d01bddf
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
914 1 _ |y 2025
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-20
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-20
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-20
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-20
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-20
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b WORLD J UROL : 2022
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-20
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-20
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-20
920 1 _ |0 I:(DE-He78)E140-20160331
|k E140 ; E140
|l NWG-KKE Intelligente Systeme und Robotik in der Urologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E140-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21